Trius pockets $30M in second venture round

San Diego-based Trius Therapeutics has snagged a $30 million round of venture capital to advance its antibacterial drug TR-701, which is now completing Phase I testing. The round was led by Kleiner, Perkins, Caufield and Byers (KPCB). New investor FinTech Global Capital also participated in the developer's second round, along with all existing investors--Sofinnova Ventures, Versant Ventures, Interwest Partners and Prism VentureWorks. 

"The excellent results from our ongoing Phase I trial, including data confirming the potential for once-daily dosing, prompted us to raise this round of financing earlier than initially planned to accelerate the clinical development of TR-701," said Jeffrey Stein, Ph.D., CEO of Trius Therapeutics. "We are encouraged that KPCB has recognized our potential and joined our strong investor group. The proceeds from this financing will enable Trius to advance TR-701 through Phase II and into Phase III development, and to continue to invest in our pre-clinical programs."

- check out the release for more info

Related Articles:
Tips for funding a biotech start-up. Report
Biotech, emerging markets are big VC targets. Report
VC adds billions in its pursuit of biotech ventures. Report
Billion-dollar baby: Biotech still on a roll with VC funds. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.